The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
Study Type
OBSERVATIONAL
Enrollment
5,000
This is a non-interventional study.
Eisai trial site 2
Hiroshima, Japan
RECRUITINGEisai trial site 3
Kyoto, Japan
RECRUITINGEisai trial site 1
Tokyo, Japan
RECRUITINGNumber of Participants With Amyloid Related Imaging Abnormality-Oedema/Effusion (ARIA-E) and Amyloid Related Imaging Abnormality-Microhemorrhage and Hemosiderin Deposit, and Cerebellar Microhaemorrhage (ARIA-H)
Time frame: Up to 156 weeks
Number of Participants With Interruption or Discontinuation of Lecanemab After Onset of ARIA
Time frame: Up to 156 weeks
Number of Participants With Infusion Related Reaction
Time frame: Up to 156 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.